Concourse Financial Group Securities, Inc. Kronos Bio, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.56 Billion
Q2 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	BUY	$0.73 - $1.38 $0 - $0	0 New	0 $0
Q1 2024 Apr 30, 2024	BUY	$1.02 - $1.3 $0 - $0	0 New	0 $0
Q4 2023 Feb 07, 2024	BUY	$0.75 - $1.49 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$1.23 - $2.25 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	BUY	$1.23 - $2.25 $0 - $0	0 New	0 $0

Q2 2023 Aug 10, 2023	BUY	$1.24 - $1.92 $0 - $0	0 New	0 $0
Q1 2023 May 15, 2023	BUY	$1.34 - $2.62 $0 - $0	0 New	0 $0
Q4 2022 Jan 30, 2023	BUY	$1.44 - $3.44 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$3.35 - $5.55 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$3.12 - $7.52 $0 - $0	0 New	0 $0
Q1 2022 May 09, 2022	BUY	$6.26 - $14.42 $0 - $0	0 New	0 $0
Q4 2021 Feb 07, 2022	BUY	$11.35 - $21.18 $0 - $0	0 New	0 $0
Q3 2021 Nov 09, 2021	BUY	$18.17 - $24.7 $0 - $0	0 New	0 $0
Q2 2021 Aug 13, 2021	BUY	$20.08 - $29.02 $0 - $0	0 New	0 $0
Q1 2021 May 13, 2021	BUY	$27.0 - $32.48 $0 - $0	0 New	0 $0
Q4 2020 Feb 02, 2021	BUY	$26.68 - $38.23 $0 - $0	0 New	0 $0

Others Institutions Holding KRON

# of Institutions

Shares Held

21.7M

Call Options Held

4.8K

Put Options Held

Bvf Inc San Francisco, CA

2.91M
Shares

$3.83 Million
0.11% of portfolio
Vida Ventures Advisors, LLC

2.77M
Shares

$3.65 Million
5.96% of portfolio
Vanguard Group Inc Valley Forge, PA

1.95M
Shares

$2.57 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

1.83M
Shares

$2.41 Million
0.0% of portfolio
Alphabet Inc. Mountain View, CA

1.44M
Shares

$1.9 Million
0.08% of portfolio

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $74.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account